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Abstract
Higher HIV diversity has been associated with virologic outcomes in children on antiretrovi-
ral treatment (ART). We examined the association of HIV diversity with virologic outcomes
in adults from the HPTN 052 trial who initiated ART at CD4 cell counts of 350–550 cells/
mm3. A high resolution melting (HRM) assay was used to analyze baseline (pre-treatment)
HIV diversity in six regions in the HIV genome (two in gag, one in pol, and three in env) from
95 participants who failed ART. We analyzed the association of HIV diversity in each geno-
mic region with baseline (pre-treatment) factors and three clinical outcomes: time to virologic
suppression after ART initiation, time to ART failure, and emergence of HIV drug resistance
at ART failure. After correcting for multiple comparisons, we did not find any association of
baseline HIV diversity with demographic, laboratory, or clinical characteristics. For the 18
analyses performed for clinical outcomes evaluated, there was only one significant associa-
tion: higher baseline HIV diversity in one of the three HIV env regions was associated with
longer time to ART failure (p = 0.008). The HRM diversity assay may be useful in future stud-
ies exploring the relationship between HIV diversity and clinical outcomes in individuals with
HIV infection.
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Introduction
HIV genetic diversity generally increases with duration of infection [1, 2] and is influenced by
viral factors and the host immune response [3, 4]. Antiretroviral treatment (ART) may
decrease viral diversity [5]. Higher pre-treatment HIV diversity has been associated with high
viral load [6], less effective control of viremia after strategic treatment interruption [7], and
more rapid disease progression [8].
We developed a high resolution melting (HRM) assay for quantifying HIV diversity with-
out sequencing [9, 10]. The HRM diversity assay measures the melting range of DNA ampli-
cons generated from viral RNA and generates a single numeric HRM score that reflects the
level of diversity in the genomic region analyzed [9]. Higher HRM scores are associated with
higher viral diversity [10] and are highly correlated with diversity measures obtained using
next-generation sequencing [10]. HRM scores were shown to be highly reproducible in a vali-
dation study that described the performance characteristics of the HRM diversity assay [11].
Furthermore, the following factors did not have a significant impact on results obtained with
the HRM assay: HIV viral load, plasma sample volume, and number of HIV RNA copies used
for DNA template preparation [11].
The HRM diversity assay has been used to quantify diversity in multiple regions in the HIV
genome in large sample sets [1, 12–14]. Using this assay, we previously observed that higher
pre-treatment pol diversity was associated with better treatment outcomes in children, includ-
ing shorter time to viral suppression and longer time to ART failure [13]. The association
between pre-treatment HIV diversity and treatment outcomes may vary in different patient
populations and settings, reflecting viral factors (e.g., HIV subtype; viral replication mutation
rates; pre-treatment HIV drug resistance), host factors (e.g., duration of infection; pre-treat-
ment CD4 cell count and HIV viral load; serologic or cell-mediated immune responses to HIV
infection), or clinical factors (e.g., treatment regimens; adherence to treatment). The associa-
tion between pre-treatment HIV diversity and treatment outcomes is also likely to vary in dif-
ferent regions of the HIV genome, since the degree of viral diversity and the rate of viral
diversification vary across the HIV genome, and since different regions of the HIV genome
(e.g., env, gag, pol) are subjected to different selective pressures, both before and after treatment
initiation [15]. The relationship between pre-treatment viral diversity and treatment outcomes
are likely to be complex. For example, higher viral replication and/or mutation rates could be
associated with higher pre-treatment diversity and could also favor emergence of resistant var-
iants after treatment initiation, leading to worse treatment outcomes. Alternatively, high pre-
treatment diversity could reflect a more robust immune response to HIV infection, which
could enhance viral suppression after treatment initiation, leading to better treatment out-
comes. In this report, we evaluated factors associated with pre-treatment HIV diversity and
the relationship between pre-treatment HIV diversity and treatment outcomes in HIV-
infected adults who initiated ART at higher CD4 cell counts.
Methods
Study cohort
Samples were obtained from the HIV Prevention Trials Network (HPTN) 052 trial, a Phase 3,
randomized controlled trial, that enrolled HIV-1 serodiscordant couples at 13 sites in Africa,
Asia, and the Americas (NCT00074581) [16, 17]. HIV-infected index participants had a CD4
cell count between 350–550 cells/mm3 at enrollment and were randomized to start ART
immediately (early ART arm) or once their CD4 cell count fell below 250 cells/mm3 on two
consecutive visits or upon development of an AIDS-defining condition (delayed ART arm).
Participants reported that they were ART naïve prior to enrollment; prior short-term ARV use
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for prevention of mother-to-child transmission was permitted [16, 17]. In this study, we ana-
lyzed enrollment (baseline/pre-treatment) samples from index participants in the early ART
arm who failed ART by May 2011; after May 2011, all index participants were offered ART at
any CD4 cell count based on interim study findings.
Laboratory methods
HIV viral load and CD4 cell count testing were performed at study sites. HIV genotyping was
performed at four study sites (Pune and Chennai, India; Johannesburg, South Africa; Rio de
Janeiro, Brazil) and at the HPTN Laboratory Center (Baltimore, MD); this testing was per-
formed using the ViroSeq HIV-1 Genotyping System (Abbott Molecular, Des Plaines, IL).
HIV subtypes were determined by phylogenetic methods, as previously described [18].
Plasma samples from index participants with baseline viral loads >400 copies/mm3 were
analyzed with the HRM diversity assay, as previously described [1, 9]. In short, HIV diversity
was quantified in six regions of the HIV genome: GAG1 (HXB2:1998–2097), GAG2
(HXB2:2068–2278), POL (HXB2:2373–2597), ENV1 (HXB2:7798–8036), ENV2 (HXB2:7950–
8119), and ENV3 (HXB2:8016–8299). Region-specific amplification of template DNA was per-
formed in the presence of a fluorescent, duplex-dependent, intercalating dye. The amplicons
were melted using a LightScanner instrument (Model HR 96, BioFire Diagnostics Inc., Salt
Lake City, UT) and the release of dye during melting was quantified. An automated software
tool (DivMelt, version 1.0.2) was used to calculate the HRM score for each region in each sam-
ple; HRM scores are defined as the temperature range over which DNA melting occurred [10].
Statistical analysis
Viral suppression was defined as occurring at the first of two study visits after ART initiation
where the viral load was400 copies/mL. ART failure was defined as occurring at the first of
two study visits after 24 weeks on ART where the viral load was >1,000 copies/mL. Chi-square
and Wilcoxon rank sum tests were used for categorical and continuous variables, respectively.
Median regression analyses were used to evaluate associations between HRM scores and base-
line demographic and clinical characteristics for each region. Cox proportional hazards regres-
sion was used to assess associations between each region and time to virologic suppression or
time to ART failure; logistic regression was used to assess associations between each region
and ARV resistance at failure. The Benjamini-Hochberg correction [19] was used to adjust for
multiple comparisons, using a false discovery rate of 0.20. All statistical analyses were per-
formed using SAS version 9.4.
Ethical considerations
Institutional Review Boards/Ethics Committees at each participating institution approved
the HPTN 052 trial (S1 Table). Written informed consent was obtained from all study
participants.
Results
Samples used for analysis
In HPTN 052, 95 index participants in the early ART arm failed ART by May 2011. Baseline
(pre-ART) HRM scores were obtained for six regions of the HIV genome (GAG1, GAG2,
POL, ENV1, ENV2, and ENV3) for 86 (90.5%) of the 95 participants; nine participants were
excluded from analysis (two had pre-ART viral loads400 copies/mL; six had no baseline
sample available; one sample failed amplification in the gp41 region, S2 Table). No significant
HIV diversity and ART outcomes
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differences in baseline demographic, laboratory, or clinical characteristics were observed
between those who were vs. were not included in the study (S3 Table). HIV subtypes were
determined for 85/86 samples. The majority of the samples were subtype C (n = 66). The HIV
subtypes of the other 19 samples were: B (n = 9), F1 (n = 4), A1 (n = 3), A2 (n = 1), CRF1_AE
(n = 1), and unique recombinant (n = 1).
Factors associated with baseline HIV diversity
Associations between baseline HIV diversity and demographic, laboratory and clinical charac-
teristics were evaluated using HRM scores generated for each region (Table 1).
In univariate analysis, HRM scores for ENV2 were associated with geographical region
(p = 0.017); this difference was not statistically significant when the data were corrected for
multiple comparisons. The median (interquartile range [IQR]) ENV2 HRM scores were 5.4
(4.5, 6.0) for South America, 5.1 (4.4, 5.6) for Asia, and 4.4 (4.1, 5.4) for Africa (S1 Fig). ENV2
HRM scores were lower for subtype C than non-subtype C HIV (median [IQR]: 4.73 [4.15–
5.54] vs. 5.21 [4.61–5.94]), but this difference was not statistically significant (p = 0.39). There
was a trend of lower ENV3 diversity and baseline drug resistance (p = 0.049). However,
this association was not statistically significant when the data were corrected for multiple
comparisons.
Association of baseline HIV diversity and treatment outcomes
Overall, 39.5% of the 86 participants were virally suppressed by 6 months, the median time
to ART failure was 8.8 months (IQR: 6.0–11.9), and 33.7% had ARV drug resistance at ART
failure. The associations of baseline diversity with time to viral suppression, time to ART fail-
ure, and ARV drug resistance at ART failure were evaluated using a dichotomous measure
(> median HRM score vs.median HRM score for each region, Table 2).
Higher baseline ENV1 HRM scores were associated with longer time to ART failure (hazard
ratio [HR]: 0.56, 95% confidence intervals [CI]: 0.36–0.89, p = 0.008); this association was still
statistically significant when the data were corrected for multiple comparisons. The association
of ENV1 diversity and time to ART failure was further supported by Kaplan-Meier analysis
(S2 Fig). Diversity in GAG1, GAG2, POL, ENV2, and ENV3 was not associated with any of
the three treatment outcomes. Other factors, such as baseline viral load, baseline CD4 cell
count, and age were not associated with time to viral suppression or time to ART failure (data
not shown). ENV1 HRM scores were similar for subtype C vs. non-subtype C HIV (median
Table 1. Association of baseline HIV diversity with baseline demographic, laboratory, and clinical characteristics*.
Variable GAG1 GAG2 POL ENV1 ENV2 ENV3
Sex 0.53 0.66 0.31 0.39 0.13 0.51
Age category 0.75 0.87 1.00 0.53 0.89 0.46
Education level 0.88 0.17 0.67 0.61 0.99 1.00
Geographical region 0.19 0.28 0.52 0.78 0.017 0.50
CD4 (per 100 CD4 increment) 1.00 0.58 0.39 0.15 0.38 0.30
VL (per unit log10 VL increment) 0.74 0.78 0.52 0.28 0.51 0.32
ARV resistance 0.19 0.84 0.39 0.07 1.00 0.049
Previous ARV for PMTCT 0.47 0.10 0.28 0.33 0.58 0.58
Abbreviations: VL: viral load; ARV: antiretroviral; PMTCT: prevention of mother-to-child transmission.
* Univariate quantile (median) regression analysis was used for all variables. None of the p-values was considered significant after adjusting for multiple
comparisons using the Benjamini-Hochberg correction.
https://doi.org/10.1371/journal.pone.0177281.t001
HIV diversity and ART outcomes
PLOS ONE | https://doi.org/10.1371/journal.pone.0177281 May 8, 2017 4 / 9
[IQR]: 4.65 [4.10–5.23]) vs. 4.50 [4.01–4.91]), but this difference was not statistically significant
(P = 1.00).
Discussion
In this study, we analyzed baseline HIV diversity among HIV-infected participants from the
HPTN 052 trial who initiated early ART and subsequently failed treatment. We measured HIV
diversity in two regions in gag (GAG1, GAG2), one region in pol (POL), and three regions in
env (ENV1, ENV2, ENV3) using the HRM diversity assay. After correcting for multiple com-
parisons, we did not observe any association between baseline (pre-treatment) HIV diversity
and any of the demographic, laboratory, or clinical characteristics evaluated. We also did not
observe any associations between HIV diversity and time to viral suppression or ARV resis-
tance at ART failure. A significant association was observed for higher baseline diversity in
one of the three env regions (ENV1) and longer time to ART failure; diversity in the other five
regions analyzed, including two other regions in env, was not associated with this outcome.
The association between ENV1 and time to ART failure was not confounded by other factors,
such as viral load, CD4 cell count, or age. In another study of participants in HPTN 052, those
factors were associated with treatment outcomes [20]. Previous studies have examined the
relationship between HIV diversity and viral load. One study found an association between
higher env diversity and higher viral load [21]. Another study found an association between
higher gag diversity and higher viral load, with no association between env diversity and viral
Table 2. Associations of baseline HIV diversity and treatment outcomes*.
Region Outcome Hazard/Odds Ratio (95% CI) p-value
GAG1 Time to viral suppression 1.20 (0.63, 2.30) 0.58
Time to ART failure 0.97 (0.63, 1.50) 0.90
Resistance at failure 0.53 (0.20, 1.37) 0.19
GAG2 Time to viral suppression 1.39 (0.73, 2.66) 0.32
Time to ART failure 0.74 (0.48, 1.14) 0.17
Resistance at failure 0.67 (0.27, 1.68) 0.40
POL Time to viral suppression 1.22 (0.64, 2.33) 0.54
Time to ART failure 0.74 (0.48, 1.15) 0.19
Resistance at failure 0.62 (0.24, 1.58) 0.32
ENV1 Time to viral suppression 1.67 (0.87, 3.21) 0.12
Time to ART failure 0.56 (0.36, 0.86) 0.008
Resistance at failure 0.42 (0.16, 1.10) 0.08
ENV2 Time to viral suppression 0.86 (0.45, 1.66) 0.66
Time to ART failure 1.25 (0.81, 1.95) 0.31
Resistance at failure 0.62 (0.25, 1.57) 0.32
ENV3 Time to viral suppression 0.99 (0.52, 1.88) 0.97
Time to ART failure 1.11 (0.72, 1.73) 0.63
Resistance at failure 0.50 (0.20, 1.27) 0.15
Abbreviations: CI: confidence interval; ART: antiretroviral therapy.
* Hazard ratios for both time to viral suppression (censored at 12 months after ART initiation) and time to
ART failure were estimated using Cox proportional hazards regression. Odds ratios for antiretroviral drug
resistance at failure were estimated using logistic regression. In all analyses, viral regions were modelled
using binary indicators based on median HRM score, with the reference as the group at or below the median
HRM score. The Benjamini-Hochberg correction was used to adjust for multiple comparisons; a single p-
value was statistically significant (shown in bold text).
https://doi.org/10.1371/journal.pone.0177281.t002
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load [15]. In our previous study of HIV-infected children, we found no association between
viral load and diversity in gag or pol and with a borderline association in env [13].
Higher levels of env diversity prior to ART initiation might reflect a higher baseline viral
replication rate and/or a higher viral mutation rate; either of these factors could make it more
difficult to suppress viral replication with ART. The association of higher pre-treatment ENV1
diversity and longer time to ART failure that we observed in this study differs from our find-
ings in a pediatric cohort. In that study, higher pre-treatment ENV2 diversity was associated
with a worse treatment outcome (shorter time to ART failure) [13]; ENV1 diversity was not
associated with any treatment outcomes in that study [13]. In another pediatric study, we
found that higher pre-treatment ENV1 and ENV2 diversity was associated with lack of viral
suppression, another bad outcome [14]. It is difficult to compare results from HPTN 052 and
these pediatric cohorts, since the treatment regimens were different and many other factors
could have impacted treatment outcomes.
The different associations that we observed for HIV diversity in the ENV1 region and other
regions analyzed (ENV2, ENV3, GAG1, GAG2, POL) could reflect differences in the mutation
rates in these regions of the HIV genome. Alternatively, the different associations could reflect
differences at the protein level. For example, anti-HIV antibodies and cytotoxic T lymphocytes
(CTLs) target different regions of the HIV genome; this could impact diversification in these
regions if selective pressures varied from one region to another. Different domains of HIV pro-
teins encoded by each HRM region may also vary in the degree of structural constraint; this
could hinder or facilitate diversification in the respective coding regions of the HIV genome.
In this study, higher diversity in the ENV1 region was associated with a longer time to viro-
logic failure. ENV1 encodes the heptad repeat 1 (HR1) region of gp41 and regions to either
side of that domain. ENV2 encodes the immunodominant region (IDR) cluster 1 of gp41 and
portions of HR1 and heptad repeat 2 (HR2). ENV3 encodes HR2 and regions to either side of
that domain [22]. It is not clear why diversity in these regions would have different associa-
tions with clinical outcomes in this study and previous reports. It is also possible that the statis-
tically significant association observed in this study did not reflect a biologic association, but
was due to chance.
This study was also limited to participants in the early ART arm of HPTN 052, who started
and failed ART before interim study results were released (before May 2011). In this group,
participants initiated ART at higher CD4 cell counts; they did not know if ART would prevent
HIV transmission to their partners, or if there were any health benefits or risks associated with
early ART. This may have impacted adherence to treatment. Another limitation is that treat-
ment adherence was not evaluated in this study. Of note, we did not find an association of
HIV diversity and treatment outcomes when we examined different regions of env. Variation
in genetic diversity in different sub-regions of HIV env may reflect variations in targeting of
antibodies or cytotoxic T lymphocyte (CTL) responses to different epitopes on envelope pro-
teins; however, serologic data was not available in this study. Variations in the mutation rate in
different regions of the env gene, or other factors may also impact env diversity. These results
highlight the complexity of the relationship between HIV diversity and treatment outcomes.
In this report, we found an association of ENV2 diversity and geographical region, with the
highest diversity in South America and the lowest diversity in Africa. This association did not
appear to reflect differences in HIV subtype, since ENV2 HRM scores were similar in partici-
pants infected with subtype C vs. non-subtype C HIV. This regional difference in ENV2 diver-
sity was not observed when the data were corrected for multiple comparisons. However,
because some of the variables included in this analysis may not be independent, the correction
may mask a true association.
HIV diversity and ART outcomes
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Env diversity has also been associated with differences in disease progression, which was
not examined in this report. Those studies have produced conflicting results. Studies using
sequencing methods to quantify diversity have observed associations between higher env
diversity and either more rapid disease progression [7, 8, 23, 24] or slower disease progression
[25–27]. The different methods for testing and different HIV genomic regions analyzed in
those studies make it difficult to compare results across the studies.
The HRM diversity assay is a high-throughput assay that can be used to analyze multiple
genomic regions in large sample sets. For example, this study included six diversity measures
in 86 samples (516 diversity measures). This approach for quantifying HIV diversity may be
useful in future studies evaluating the complex relationship between HIV diversity, ART out-
comes, and other clinical outcomes in HIV infection.
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